Citrine Global Q2: Pre-revenue, $3K cash, heavy related-party debt; Israeli grant offers lifeline

Citrine Global, Corp (PINK: CTGL) - Q2 2024 snapshot (Form 10‑Q filed)

All dollar amounts taken from the filing are U.S. dollars in thousands unless noted.

What's happening inside the company
* Parent and core operations are based in Israel through CTGL Citrine Global Israel Ltd. and majority-owned Cannovation (renamed SkyTech Orion Ltd.).
* The company has no product revenues to date - still pre‑revenue and focused on R&D, commercialization planning and building an Operational Innovation Center on government‑subsidized land in Yerucham, Israel.
* Significant related‑party activity: large portion of G&A and accrued compensation are related‑party; convertible notes and loans are largely with related parties and some conversions into equity occurred.
* Key corporate moves after the period: conversion of convertible debt to equity, multiple consulting/investment agreements, a government grant to the Israeli subsidiary, and name changes reflecting a pivot toward UAV/drone/defense production (SkyTech).

Balance sheet - key statistics (June 30, 2024 vs Dec 31, 2023)
* Total assets: 1,601 vs 2,486.
* Cash and cash equivalents: 3 vs 7.
* Total current assets: 128 vs 258.
* Investments (measurement alternative): 1,263 vs 2,010.
* Total liabilities: 5,368 vs 4,961.
* Convertible notes (related parties): 2,260 (as of June 30, 2024).
* Total stockholders' deficit: (3,767) vs (2,475).
* Accumulated deficit: (31,009) vs (29,507).
* Shares outstanding: 1,044,074,409 as of June 30, 2024 (and 1,234,185,009 as of Sept 3, 2025).

Income statement / P&L - concise positives and negatives
* Positive: Operating loss improved - six months operating loss 667 (H1 2024) vs 1,081 (H1 2023). Net loss improved slightly: 1,502 vs 1,528 for the six‑month periods. Marketing/G&A (total) declined for the six months (667 vs 1,024).
* Negative: Still pre‑revenue - zero revenues reported for the three‑ and six‑month periods. Major non‑cash financing charges drove large reported losses: fair value measurement of IBOT options hit (747) in the six months and (932) in the quarter. Financing expenses (non‑cash and interest) are material - financing expenses, net were 835 (six months) and 986 (quarter), contributing heavily to net loss. Net loss (three months) worsened to (1,250) vs (676) year‑over‑year due to option fair‑value charges.
* Key P&L figures (six months ended June 30, 2024): Research & development 0, Marketing/G&A related parties (455) + Marketing/G&A (212) = operating loss (667); financing expenses, net (835); net loss (1,502). Loss per share is negligible per share (< $0.01) given share count and rounding.

Cash flow and liquidity
* Net cash used in operating activities: (30) for six months (improved from (97)).
* Net cash provided by financing activities: 26 (six months).
* Cash at period end: 3 (very low).
* Working capital deficiency: reported ~2,980 (negative working capital).
* Management notes access to a credit facility (Cannovation credit line) and believes funds are sufficient for next 12 months - but this depends on continued support, credit draws, and execution of planned financings.

Material events after the period (important tail risks/rewards)
* Government grant to Cannovation (SkyTech Orion Ltd.): NIS 12.5 million (~USD 3.4 million) awarded Jan 12, 2025 for reimbursements of eligible project expenses - a major funding and validation point for the Yerucham project.
* Significant convertible debt conversions to equity (Dec 31, 2024) reduced cash obligations but produced dilution and issued warrants (large share/warrant pools exercisable at $0.01).
* Credit facility activity and guarantees: SR Accord draws, extensions and personal guarantees by management/related parties increase contingent exposure.
* Filing delinquencies resulted in restricted trading and no active market at one point - a major liquidity and investor‑access issue.

Risks and red flags
* Zero revenue and sustained net losses; short cash runway on reported balances (cash = 3).
* Heavy reliance on related‑party funding, conversions, and guarantees - governance and independence risks.
* Large non‑cash volatility from fair‑value accounting (IBOT options) can swing earnings materially quarter to quarter.
* Working capital deficit and liabilities exceed assets - negative equity position at the consolidated level.
* Geopolitical risk: primary operations in Israel during an active conflict; operations and commercialization are explicitly affected by the war.
* Significant dilution risk from large option/warrant pools and past/share conversions at low exercise prices.

Positives to watch
* Government grant (~NIS 12.5m / ~$3.4m) awarded to the Israeli subsidiary supports the Yerucham facility and could unlock project progress and third‑party funding.
* Debt conversions to equity reduce near‑term cash servicing needs and simplify balance sheet cash flow obligations (but dilute holders).
* Operating expense control trends (lower marketing/G&A in the reported six‑month period) and reduced net cash used in operations vs prior period.

Bottom line (straightforward)
* Citrine Global, Corp (PINK: CTGL) is a pre‑revenue botanical/wellness platform with a major Israeli real‑estate and production project (Yerucham) and a recent grant that materially improves project funding prospects. However, the company shows acute liquidity stress on reported balances (cash = 3), persistent losses driven this quarter by large non‑cash financing items, heavy related‑party financing and guarantees, balance‑sheet deficit, and significant dilution risk. Investors should treat the story as high‑risk / high‑execution dependency: the government grant and successful project execution are the key potential positives; lack of revenue, low cash, related‑party exposure and restricted trading are the primary negatives.

Source: Citrine Global, Corp. Form 10‑Q for period ended June 30, 2024 (filed / signed Sept 3, 2025). Numbers and quotes are taken directly from the filing.